It was predicted to cause potential disruption to the transit peptide on our in silico structural analysis and tumor analysis was reported to show loss of heterozygosity and loss of SDHA immunostaining (one limitation to this study was only three SDHA exons were sequenced and another undetected mutation might have been present in cis) (Italiano et al. The gene discussed is SDHA; the disease is neoplasm.